Reply to: "Inhibitory effects of colchicine on inflammasomes"

Affiliations

¹ Division of Cardiovascular Diseases, Pontificia Universidad Católica, Santiago, Chile. Electronic address: gjmartin@uc.cl.
² Department of Cardiology, Royal Prince Alfred Hospital, Sydney Medical School, The University of Sydney and Heart Research Institute, Sydney, New South Wales, Australia.

Comment

Gonzalo J Martínez et al. Atherosclerosis. 2018 Jun.

. 2018 Jun:273:155-156.

doi: 10.1016/j.atherosclerosis.2018.03.042. Epub 2018 Mar 28.

¹ Division of Cardiovascular Diseases, Pontificia Universidad Católica, Santiago, Chile. Electronic address: gjmartin@uc.cl.
² Department of Cardiology, Royal Prince Alfred Hospital, Sydney Medical School, The University of Sydney and Heart Research Institute, Sydney, New South Wales, Australia.

No abstract available

Keywords: Atherosclerosis; Colchicine; IL-1beta; NLRP3 inflammasome.

Comment on

The NLRP3 inflammasome and the emerging role of colchicine to inhibit atherosclerosis-associated inflammation.
Martínez GJ, Celermajer DS, Patel S. Martínez GJ, et al. Atherosclerosis. 2018 Feb;269:262-271. doi: 10.1016/j.atherosclerosis.2017.12.027. Epub 2017 Dec 25. Atherosclerosis. 2018. PMID: 29352570 Review.
Inhibitory effects of colchicine on inflammasomes.
Hoss F, Latz E. Hoss F, et al. Atherosclerosis. 2018 Jun;273:153-154. doi: 10.1016/j.atherosclerosis.2018.02.026. Epub 2018 Mar 2. Atherosclerosis. 2018. PMID: 29526464 No abstract available.